Nkg2D

Advanced cell therapy based on the chimeric receptor NKG2D: the NK-T cell approach

Miltenyi Biotec

Insights into NKG2D-targeting CAR-T cells in R/R AML

VJHemOnc – Video Journal of Hematology & HemOnc

NKG2D-based CAR-T in R/R AML and MDS

VJHemOnc – Video Journal of Hematology & HemOnc

NKG2D CAR T-cells & soluble NKG2D ligands

VJHemOnc – Video Journal of Hematology & HemOnc

NKG2D CAR T-cells & soluble NKG2D ligands

VJHemOnc – Video Journal of Hematology & HemOnc

NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells

International Myeloma Foundation

NKG2D CARs for R/R AML and MDS

VJHemOnc – Video Journal of Hematology & HemOnc

NKG2D CAR-T cell therapy in AML/MDS

VJHemOnc – Video Journal of Hematology & HemOnc

THINK trial: Phase I results for NKG2D CAR-T therapy in AML

VJHemOnc – Video Journal of Hematology & HemOnc

Natural Killer Cells: How Do They Kill Selectively?

Catalyst University

Natural killer cells remember - Lewis Lanier

Wellcome Connecting Science Learning and Training

Natural Killer cells | Top 5 ways Natural Killer cells work

Friendly Neighborhood Immunologist

Michael Dustin (Oxford, NYU School of Medicine) 2: The Immunological Synapse: Signaling and Function

Science Communication Lab

Las células NK primarias transducidas con NKG2D-CAR apuntan eficientemente a las células MM

International Myeloma Foundation

Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease

Gut

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors | RTCL.TV

Medicine RTCL TV

Developing a new generation of CAR T-cell therapies for solid tumors

Eui-Cheol Shin: Hepatitis Virus-specific and Bystander CD8+ T Cells in Viral Hepatitis

ProImmune thinkpeptides

Martin Meyerson Berkeley Faculty Research Lecture: David H. Raulet

UC Berkeley Events